论文部分内容阅读
目的探讨分析大肠癌异时性肝转移的临床特点、预后的影响因素及不同治疗手段的疗效差异,为大肠癌异时性肝转移的临床诊疗提供参考。方法本文采用统计学列联分析方法对收集的80例大肠癌异时性肝转移患者的临床资料进行分析,并随访其预后。结果 80例大肠癌异时性肝转移患者男性多于女性,病理的类型以中分化管状腺癌为主。3年生存率为30%。列联分析结果显示P值小于0.05的因素有CEA水平、脉管癌栓、淋巴结转移数、术后至肝转移时间、治疗方法,说明这些因素对预后有一定的影响。结论肝转移大小、发生时间、术前CEA水平、脉管癌栓、淋巴结转移数及治疗方式是影响大肠癌肝转移的相关因素。肝转移灶手术切除+化疗的患者生存率高于射频消融加全身化疗、肝动脉栓塞化疗、姑息化疗、中医中药等治疗的患者,效果较好,但临床上应根据适应证选择合理的治疗方法,以使患者最大地获益。
Objective To investigate the clinical characteristics of heterotopic liver metastasis of colorectal cancer, the influencing factors of prognosis and the curative effects of different treatment methods, so as to provide reference for the clinical diagnosis and treatment of patients with hepatic metastasis of colorectal cancer. Methods The clinical data of 80 cases of patients with hepatic metastasis of colorectal cancer collected from the collected colorectal cancer patients were analyzed by the statistical method of cluster analysis and their prognosis was followed up. Results 80 cases of patients with heterotopic liver metastasis of colorectal cancer more than women, the type of pathological differentiation of the main tubular adenocarcinoma. 3-year survival rate was 30%. The results of contingency analysis showed that the factors of P value less than 0.05 were CEA level, vascular tumor thrombus, lymph node metastasis, postoperative time to liver metastasis and treatment method, indicating that these factors have a certain impact on prognosis. Conclusion The size of liver metastasis, the time of onset, preoperative CEA level, vascular tumor thrombus, lymph node metastasis number and treatment are the related factors that affect the liver metastasis of colorectal cancer. Patients with liver metastases resection and chemotherapy survival rate higher than radiofrequency ablation plus systemic chemotherapy, hepatic artery chemoembolization chemotherapy, palliative chemotherapy, traditional Chinese medicine and other treatment of patients, the effect is better, but the clinical indications should choose a reasonable treatment , In order to maximize the benefit of patients.